

Paediatric Cancer

Brain

In Development

SIOP Ependymoma II; An International Multi Centre Clinical Program for the diagnosis and treatment of children, adolescents and young adults with Ependymoma	ependymoma@trials.bham.ac.uk
PNET5 : An international prospective study on clinically standard-risk medulloblastoma in children with low-risk biological profile (PNET5 MB-LR) or average-risk biological profile (PNET5 MB-SR)	pnet5@trials.bham.ac.uk
VINILO : Phase I-II Study of Vinblastine in Combination with Nilotinib in Children, Adolescents and Young Adults with Refractory or Recurrent Low-Grade Glioma.	vinilo@trials.bham.ac.uk
INTREPID : A phase I dose escalation study of intrathecal Etoposide as a continuous infusion investigating duration and rate of infusion in patients with leptomeningeal metastatic brain cancer	intrepid@trials.bham.ac.uk

Germ Cell

Open

SIOP CNS GCT II : Prospective trial for the diagnosis and treatment of children, adolescents and young adults with intracranial germ cell tumours	siopcns-gctii@trials.bham.ac.uk
--	--

Embryonic Tumour

Open

HRNBL : High risk neuroblastoma study 1 of SIOP- Europe (SIOPEN)	hrnbl@trials.bham.ac.uk
LuDO : A phase IIa study of 177Lutetium dotatate in children with primary refractory or relapsed high risk neuroblastoma.	ludo@trials.bham.ac.uk
GD2 : A Phase I/II dose schedule finding study of CH14.18/CHO continuous infusion combined with subcutaneous aldesleukin (IL-2) in patients with primary refractory or relapsed neuroblastoma	gd2@trials.bham.ac.uk
BEACON : A randomised phase IIb trial of BEvACizumab added to Temozolomide ± Irinotecan for children with refractory/relapsed Neuroblastoma - BEACON-Neuroblastoma Trial	beacon@trials.bham.ac.uk

In Development

IMAT : A randomised phase I/II study of intensity modulated arc therapy techniques in abdominal neuroblastoma	imat@trials.bham.ac.uk
--	--

Haematology Malignancies

Open

EuroNet PHL-LP1 : First International Inter-Group Study for Nodular Lymphocyte Predominant Hodgkin's Lymphoma in Children and Adolescents	euronetphl-lp1@trials.bham.ac.uk
Interfant 06 : International collaborative treatment protocol for infants under one year with acute lymphoblastic or biphenotypic leukaemia (LK 2006 10)	interfant06@trials.bham.ac.uk
UKALL 2011 : United Kingdom National Randomised Trial for Children and Young Adults with Acute Lymphoblastic Leukaemia and Lymphoma 2011	ukall2011@trials.bham.ac.uk
Inter-B-NHL 2010 : Intergroup trial for children or adolescents with B-Cell NHL or B-AL: evaluation of rituximab efficacy and safety in high risk patients	interbnhl@trials.bham.ac.uk

In Development

NECTAR: A Phase I trial of NECTAR (Nelarabine, Etoposide and cyclophosphamide in T-ALL relapse): A joint study of TACL and POETIC	nectar@trials.bham.ac.uk
MyeChild 01: International randomised phase III clinical trial in children with acute myeloid leukaemia with an embedded dose finding study for gemtuzumab ozogamicin in combination with induction chemotherapy	Myechild01@trials.bham.ac.uk
EuroNet PHL-C2: Second International Inter-Group Study for Classical Hodgkin's Lymphoma in Children and Adolescents	TBA

Histiocytosis

In Development

LCH IV: International collaborative treatment protocol for children and adolescents with langerhans cell histiocytosis	Ichiv@trials.bham.ac.uk
---	--

Sarcoma

Open

RMS 2005: A protocol for non-metastatic rhabdomyosarcoma (STS 2006 04)	rms2005@trials.bham.ac.uk
VIT0910: International randomised phase II trial of the combination of Vincristine and Irinotecan with or without Temozolomide (VI or VIT) in patients with refractory or relapsed Rhabdomyosarcoma	vit0910@trials.bham.ac.uk
EE2012: International randomised controlled trial for the treatment of newly diagnosed Ewing's sarcoma family of tumours	ee2012@trials.bham.ac.uk
rEECur: International Randomised Controlled Trial of Chemotherapy for the treatment of recurrent and primary refractory Ewing sarcoma	reecur@trials.bham.ac.uk

Adult Cancer

Bladder

Open

TUXEDO: Phase I/II feasibility study of cetuximab with 5FU and Mitomycin C or cisplatin with concurrent radiotherapy in muscle invasive bladder cancer	tuxedo@trials.bham.ac.uk
---	--

Breast

Open

LORIS: Can patients with newly diagnosed low-grade DCIS safely avoid surgery, without detriment to their psychological well-being and can those patients who require surgery be identified by pathological and radiological criteria?	loris@trials.bham.ac.uk
--	--

In Development

ROSCO: Response to Optimal Selection of neo-adjuvant Chemotherapy in Operable breast cancer	rosco@trials.bham.ac.uk
--	--

Haematological Malignancies

Open

CyCLLe: An early phase II trial of Cyclosporin A in early adverse risk CLL	cyclle@trials.bham.ac.uk
De-Iron: A phase II study of the efficacy and safety of Deferasirox administered at early iron loading in patients with transfusion-dependent Myelodysplastic Syndromes	de-iron@trials.bham.ac.uk
EIAstic: A phase Ib study of Eltrombopag and Azacitidine in patients with high risk myelodysplastic syndromes and related disorders	elastic@trials.bham.ac.uk
HA-1: A phase I clinical trial of the vaccination of healthy human volunteers against the minor histocompatibility antigen (mHA) HA-1 using a DNA and MVA 'prime/boost' regimen	ha1@trials.bham.ac.uk
LenaRIC: Phase II study of the adjunctive use of lenalidomide in patients undergoing reduced intensity conditioning allogeneic transplantation for multiple myeloma	lenaric@trials.bham.ac.uk
FIGARO: A Randomised Trial of the FLAMSA-BU Conditioning Regimen in Patients with Acute Myeloid Leukaemia and Myelodysplasia Undergoing Allogeneic Stem Cell Transplantation	figaro@trials.bham.ac.uk
MAJIC: A phase II study of Ruxolitinib (INCB424) in patients with High Risk Polycythaemia Vera or Essential Thrombocythaemia resistant to or intolerant of standard therapy	majic@trials.bham.ac.uk
RAvVA: A Randomised Phase II Trial of 5-Azacitidine versus Vorinostat in Combination with 5-Azacitidine in patients with Newly Diagnosed, Relapsed or Refractory Acute Myeloid Leukaemia or High Risk Myelodysplastic Syndrome ineligible for intensive chemotherapy	ravva@trials.bham.ac.uk
ROMAZA: Phase I trial of Romidepsin plus Azacitidine combination therapy in patients with newly diagnosed, relapsed or refractory Acute Myeloid Leukaemia ineligible for salvage chemotherapy	romaza@trials.bham.ac.uk
BREVITY: A phase II study of brentuximab vedotin (SGN-35) using a response adapted design in patients with Hodgkin lymphoma unsuitable for chemotherapy due to age, frailty or co-morbidity	brevity@trials.bham.ac.uk
IcICLLe: Assessment of the mechanism of action of PCI-32765 in B-cell receptor pathway inhibition in CLL	iciclle@trials.bham.ac.uk

Viola: A Phase I Trial of Combined Azacitidine and Lenalidomide Salvage Therapy in Patients with Acute Myeloid Leukaemia who Relapse after Allogeneic Stem Cell Transplantation	viola@trials.bham.ac.uk
Matchpoint: Management of Transformed CHronic myeloid leukaemia: POnatinib and INTensive chemotherapy: a dose-finding study	matchpoint@trials.bham.ac.uk
TIER: A Phase I/II Study of Thiotepa, Ifosfamide, Etoposide and Rituximab for the treatment of relapsed and refractory primary central nervous system lymphoma	tier@trials.bham.ac.uk

In Development

CALiBR: Assessment of the mechanism of action of CAL-101 in B-cell receptor pathway inhibition in CLL	calibre@trials.bham.ac.uk
RomiCar: Phase I/II study to determine the maximum tolerated dose and overall response rate of the combination of romidepsin and carfilzomib in relapsed or refractory peripheral T-cell lymphoma	romicar@trials.bham.ac.uk
PHAZAR: A phase Ib study to assess the safety and tolerability of oral Ruxolitinib in combination with 5-azacitidine in patients with accelerated phase myeloproliferative neoplasms, myelodysplastic syndromes(MDS) or acute myeloid leukaemia (AML)	phazar@trials.bham.ac.uk
Bubble: Phase 1B Study of buparlisib with Bortezomib in Defined Genetic Subgroups of Patients with Relapsed or Refractory Multiple Myeloma	bubble@trials.bham.ac.uk
AZTEC: A phase II study of the use of azacitidine for the treatment of patients with chronic graft-versus-host-disease who have failed therapy with corticosteroids	Aztec@trials.bham.ac.uk
TORCH: A phase II study to determine the safety and efficacy of the dual mTORC inhibitor AZD2014 and to investigate additional toxicities in combination with rituximab in relapsed/refractory Diffuse Large B cell Lymphoma (DLBCL)	torch@trials.bham.ac.uk

Head and Neck

Open

OROMOUTH: HPV prevalence in the mouth and oropharynx of the tonsillectomy population.	oromouth@trials.bham.ac.uk
MVA: A Cancer Research UK Phase Ib trial to determine the safety, tolerability and immunogenicity of extended schedule vaccination with MVA-EBNA1/LMP2 in patients with Epstein Barr Virus positive nasopharyngeal carcinoma	can-crctu-edd@adf.bham.ac.uk

In Development

PACiFiC: Phase Ib trial of Atu027 in Combination with Cisplatin, 5-FU and Cetuximab in Patients with Head and Neck Cancer	pacific@trials.bham.ac.uk
CompARE: Phase III randomised controlled trial Comparing Alternative Regimens for escalating treatment of intermediate and high-risk oropharyngeal cancer	compare@trials.bham.ac.uk

Liver

Open

TACE-2: A randomised placebo-controlled, double-blinded, phase III trial of sorafenib in combination with transarterial chemoembolisation in hepatocellular cancer	tace2@trials.bham.ac.uk
---	--

In Development

IMMUNOTACE: A phase II randomised clinical trial of conditioning cyclophosphamide and chemoembolisation with or without vaccination with Dendritic Cells pulsed with HepG2 lysate in vivo in patients with Hepatocellular Carcinoma	immunotace@trials.bham.ac.uk
ACTICCA-1: Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma	acticca-01@trials.bham.ac.uk

Lung

Open

STOMP: A randomised phase II study of AZD2281 maintenance treatment in patients with chemosensitive small cell lung cancer	stomp@trials.bham.ac.uk
National Lung Matrix: Multi-drug, genetic marker-directed, non-comparative, multi-centre, multi-arm phase II trial in non-small cell lung cancer	lungmatrix@trials.bham.ac.uk

In Development

SPECIAL: Standard or Palliative Care In Advanced Lung cancer. Does early referral of patients with metastatic non-small cell lung cancer to UK specialist palliative care services make a difference in their quality of life or survival?	special@trials.bham.ac.uk
RUXSAC: A double blind, placebo-controlled, randomised phase II study of Pemetrexed and Cisplatin with and without Ruxolitinib in Malignant Pleural Mesothelioma	ruxsac@trials.bham.ac.uk

Prostate

Open

AdUP: A Phase I Clinical Trial of a replication defective type 5 adenovirus vector expressing nitroreductase and GMCSF (AdNRGM) given via trans-perineal, template-guided, intra-prostatic injection, followed by intravenous CB1954, in patients with locally relapsed hormone-refractory Prostate Cancer.	adup@trials.bham.ac.uk
CANTATA: A multicentre phase II randomised controlled trial evaluating cabazitaxel versus docetaxel re-challenge for the treatment of metastatic castrate refractory prostate cancer, previously treated with docetaxel at inception of primary hormone therapy	cantata@trials.bham.ac.uk

Renal

Open

PAZ02: A study of pazopanib efficacy and safety in patients with advanced clear-cell renal cell carcinoma and Performance Status 2 (ECOG)	pazo2@trials.bham.ac.uk
ADIUVO: Efficacy of adjuvant mitotane treatment in prolonging recurrence-free survival in patients with adrenocortical carcinoma at low-intermediate risk of recurrence	adiuvo@trials.bham.ac.uk

Sarcoma

Open

Axi-STs: A clinicopathological phase II study of axitinib in patients with advanced angiosarcoma and other soft tissue sarcomas	axi-sts@trials.bham.ac.uk
SCART: Phase I/II study of oral MEK inhibitor Selumetinib (AZD6244 Hydrochloride) in Combination with Highly Active Anti-Retroviral Therapy (HAART) in AIDS-associated Kaposi's sarcoma (KS).	scart@contacts.bham.ac.uk

Skin

Open

UKMCC-01: A phase II study of pazopanib in metastatic merkel cell carcinoma	ukmcc-01@trials.bham.ac.uk
SPOT: Squamous cell carcinoma Prevention in Organ transplant recipients using Topical treatments (SPOT): a feasibility study	spot@trials.bham.ac.uk

Gynaecology

Open

DESKTOP III: A randomized multicentre study to compare the efficacy of additional tumour de-bulking surgery versus chemotherapy alone for recurrent platinum-sensitive ovarian cancer	desktopIII@trials.bham.ac.uk
EPIVIN: Phase II clinical trial investigating the use of epigallocatechin-3-gallate (Veregen) in the treatment of vulval intraepithelial neoplasia	epivin@trials.bham.ac.uk

Paediatric Non-Cancer

Disease Prevention

Open

PEPTalk 2: Pilot of a randomised controlled trial to compare VZIG and aciclovir as post-exposure prophylaxis against chickenpox in children with cancer

peptalk2@trials.bham.ac.uk

Adult Non-Cancer

Liver

Open

BUTEO: A Single arm, Two-stage, Multi-centre, Phase II clinical trial investigating the safety and activity of the use of BTT1023, a vascular adhesion protein (Vap-1) in the treatment of patients with Primary Sclerosing Cholangitis (PSC)

buteo@trials.bham.ac.uk

In Development

AUTUMN: AUtologous T-regulatory cell tracking after infUision in autoiMmuNe liver disease patients

autumn@trials.bham.ac.uk

Supportive Care

In Development

FOAM: Folic acid supplementation in the management of menopausal symptoms in cancer survivors and healthy postmenopausal women

foam@trials.bham.ac.uk